Mit Ihrer Erlaubnis verwenden wir datenschutzfreundliche Analysen, um zu verstehen, welche Recherchewege funktionieren. Wir verwenden weder Werbe-Tracker noch Sitzungsaufzeichnungen. Sie können diese Auswahl in den Einstellungen ändern. Lesen Sie die Datenschutzerklärung.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
DXCM — frequently asked questions
Is DexCom, Inc. overvalued?
In our latest published analysis dated 2026-10-04, DXCM looks meaningfully overvalued. The price recorded at analysis is 85,4 USD versus our fair value of 59,0 USD; the high endpoint is presented separately as potential value of 74,0 USD. That implies roughly 30.9% downside to fair value at that date.
Our latest published report, analyzed 2026-10-04, gives DXCM a fair value of 59,0 USD and a potential value of 74,0 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for DexCom, Inc.'s archetype; it is a dated research output, not a live price.
Should I buy DXCM now?
Our latest published rating for DXCM, analyzed 2026-10-04, is Sell. DexCom, Inc. looks meaningfully overvalued at the analysis-date price of 85,4 USD versus fair value of 59,0 USD; potential value is 74,0 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for DXCM?
The dedicated bear-case section in our report analyzed 2026-10-04 documents DexCom, Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is DXCM's rating?
Our latest published rating for DXCM, analyzed 2026-10-04, is Sell, with a published moat assessment of 9/10 (Wide). It reflects our fair value of 59,0 USD, the potential value of 74,0 USD, and the price recorded at analysis (85,4 USD).
Englische Quelle wird angezeigt, während wir übersetzen
Dieser Bericht wurde noch nicht übersetzt. Aktualisieren Sie in ein paar Minuten, sobald die Übersetzungswarteschlange aufgeholt hat.
§1 ZusammenfassungEN
30-Sekunden-AntwortSell
Preis im Verhältnis zum Wert
Kurs
$85.36
Fairer Wert
$58.97
Potenzialwert
$74.00
Stand
2026-10-02
Warum es funktionieren kann
Accelerated CMS reimbursement coverage for Type 2 diabetes following validation from the CONNECT trial, paired with rapid commercial scaling at the automated Ireland production facility.
Was unsere Einschätzung ändern würde
Pharmacy rebate escalation and intensifying pricing competition from alternative CGM systems compress non-GAAP operating margin below 20.5%.
DexCom Inc. (NASDAQ: DXCM) is assigned a Sell rating with a compositeFair value of $58.97 against a market price of $85.36, representing an implied downside of -30.9% and a 44.8% price premium to intrinsic value. While DexCom retains a wide economic moat in continuous glucose monitoring (CGM) through software algorithms and automated insulin delivery pump integrations, the stock's forward P/E multiple of 28.25x overly discounts operational execution and leaves investors exposed to significant multiple contraction.
In the second quarter of 2026, DexCom demonstrated solid operational execution, generating 12% organic revenue growth and expanding new patient starts across core segments. Management raised full-year FY2026 revenueguidance to $5.18B-$5.25B (11%-13% growth) and non-GAAP operating margin guidance to 23.5%-24.0%, underpinned by line yield improvements, scrap reductions, and commercial scaling at its automated Ireland facility. For FY2025, DexCom generated $4,662.0M in revenue, $911.8M in GAAP EBIT (19.56% margin), and $1,077.2M in free cash flow.5,6,7
Our compositeFair value of $58.97 synthesizes co-primary models: forward earnings discounting ($66.90 midpoint) anchored on consensus FY2027 EPS of $3.12 and multi-stage moat fade ($62.17 midpoint) capturing DexCom's 15-year wide moat advantage. These are supported by owner earnings ($53.02 midpoint) and enterprise DCF ($38.97 midpoint) using a 9.99% WACC and 10.23% cost of equity. Current share prices ($85.36) exceed our highest model scenario ($74.00), demanding flawless execution without reflecting ongoing competitive and reimbursement hazards.1,2,4,5
DexCom's current forward P/E of 28.25x trades at a steep premium to medtech comparables such as Edwards Lifesciences (25.21x), Stryker (16.47x), and Boston Scientific (12.49x). Our Fair value is 31.6% below the present-value equivalent of the analyst consensus 12-month price target ($86.26 present value, discounted at 10.23% from $95.08). External consensus overlooks the vulnerability of revenue growth to potential CMS coverage delays past mid-2027 and customer concentration across three major drug wholesalers (Customer A 55%, B 35%, C 46%). Consequently, we reiterate our Sell rating.2,3,4,5,8
Robust Ecosystem Switching Costs and AID Pump Interoperability
DexCom's continuous glucose monitoring sensors feature deep algorithmic integration with automated insulin delivery (AID) pump leaders like Tandem and Beta Bionics, creating durable patient retention and high clinical switching barriers.5
Massive Addressable Market Expansion in Type 2 Diabetes
Compelling clinical data from the CONNECT study supports an impending CMS reimbursement coverage decision expected by late 2026, opening access to 9 million US patients with implementation targeted for mid-2027.5
Manufacturing Yield Efficiencies and Operational Leverage
Management raised full-year FY2026 non-GAAP gross marginguidance to ~64% and operating margin to 23.5%-24.0%, powered by line throughput gains and scrap reductions.5
Hausempfehlung
Sell. At $85.36 as of October 2, 2026, DexCom trades well above its compositeFair value of $58.97, leaving no margin of safety for investors despite strong underlying CGM technology and healthy free cash flow conversion.4,6
Unternehmensüberblick
DexCom, Inc. is a medical technology company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and healthcare providers. The company's core platforms include the Dexcom G6, Dexcom G7, and Stello sensor systems, which eliminate routine fingersticks by measuring glucose levels continuously in interstitial fluid and wirelessly transmitting real-time values and trend rates to compatible display devices, smartphones, and automated insulin delivery (AID) pump algorithms.
The company operates in a single operating segment focused on diabetes management systems across two major geographic areas: the United States, which contributed $3,334.9M in revenue (71.5% of total) in FY2025, and international markets, which generated $1,327.1M (28.5% of total). Commercial distribution in the US is primarily conducted through major wholesale pharmaceutical distributors and retail pharmacy networks, serving an addressable domestic diabetes population of approximately 9 million individuals.
§2 BärenszenarioEN
Under a compounding stress scenario where intense continuous glucose monitoring competition compresses non-GAAP operating margins below 20.5% (reversing progress from FY2025 GAAP EBIT of $911.8M and FY2026 guidance of 23.5%-24.0%), CMS delays type 2 non-intensive coverage decisions past mid-2027, and market multiples contract toward peer medians (16.47x for SYK), intrinsic equity value contracts toward the $47.95 lower bound of our fair value envelope. At the current trading price of $85.36, equity holders face substantial valuation downside with zero safety buffer against negative operational surprises.
In the bear path, competitive pressure forces higher formulary rebate concessions while the lack of near-term basal diabetes reimbursement constrains addressable market growth. Ireland startup costs temporarily dilute operating margins, causing growth to slow toward broader medical device sector averages.
Wie diese These scheitern kann
Severe price competition from Abbott FreeStyle Libre and pharmacy rebate escalation squeeze gross margin, compressing non-GAAP operating margin by over 300 bps.
Management guided FY2026 non-GAAP operating margin to 23.5%-24.0% with gross margin at ~64%. An erosion of operating margin below 20.5% would reverse operational leverage gains achieved over FY2025 GAAP EBIT margin of 19.56% ($911.8M on $4,662.0M revenue).
Frühwarnsignale zur Überwachung
Die fünf Entwicklungen, die unsere Anlagethese schwächen würden.
DexCom warrants a Wide economic moat rating (moat score 9.0) based on deep patient switching costs and proprietary intangible assets. As a pioneer in continuous glucose monitoring (CGM), the company has embedded its sensors into closed-loop automated insulin delivery (AID) algorithms with leading pump manufacturers, including Tandem and Beta Bionics. For intensive insulin users, moving away from DexCom disrupts calibrated dosing automation and requires clinical retraining, creating formidable barriers to churn.
The company's platform moat is further protected by proprietary sensor chemistry, manufacturing automation, and clinical dataset moats. Results from the CONNECT study demonstrated robust A1C reduction and high patient engagement across type 2 diabetes users on diverse regimens, providing the clinical foundation for an expected CMS reimbursement coverage determination before year-end taking effect in mid-2027. Concurrently, transitioning users to 15-day sensor platforms and developing G8 will provide continuous manufacturing scrap reductions and structural cost advantages over competitors.
Despite this wide economic moat, economic rent sustainability must be distinguished from equity valuation. While the moat defends operating margins at 23.5%-24.0% and delivers an ROIC of 16.43% that easily outpaces the 9.99% WACC, the prevailing equity valuation of $85.36 prices in uninterrupted perpetual growth, leaving the stock vulnerable to any compression in forward multiples.
Ökonomischer Gewinn
DexCom generates a return on invested capital of 16.43%, which comfortably exceeds its moderate cost of capital (WACC of 9.99% and moderate cost of equity of 10.23%), delivering an excess economic spread of 644 bps. In FY2025, operating profit was $911.8M on revenue of $4,662.0M, generating $1,077.2M of free cash flow and confirming durable economic rent extraction across a 15-year horizon.2,6,7
9/ 10
Wide
Sources of advantage
01High Patient and Clinical Switching Costs — DexCom sensors are deeply embedded into automated insulin delivery algorithms and hardware ecosystems with partners like Tandem and Beta Bionics. Patients and prescribing physicians face significant switching friction, training overhead, and clinical continuity risks if transitioning to alternative sensor architectures.Wide
02Proprietary Intangible Assets and Clinical Datasets — Proprietary sensor membrane chemistry, glucose-sensing algorithms, and extensive clinical validation datasets—such as the CONNECT trial demonstrating significant A1C reductions across type 2 users —create regulatory and clinical barriers that defend premium positioning against generic medtech offerings.Wide
Bekannte Bedrohungen für den Wettbewerbsvorteil
Bedrohung
Schweregrad
Zeitrahmen
Minderung
Formulary rebate escalation and price competition from peer CGM systems such as Abbott FreeStyle Libre squeezing gross margins.
medium
12-24 months
Transitioning the installed user base to lower-cost 15-day platforms and launching Stello for non-insulin users expands unit volumes, while Ireland manufacturing automation reduces unit production costs.
The highlighted cell is Fair value when every assumption sits at its base level ($58.97). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $755.0M after modeled reinvestment of $212.9M, with terminal value at 75.3% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
FY2026 revenue of $5,230.1M (12.19% growth) aligning with guidance of $5.18B-$5.25B.1,5
FY2026 non-GAAP operating margin reaches 23.75% (midpoint of guided 23.5%-24.0%), rising to 25.0% by FY2030.5
FY2027 revenue growth moderates to 10.89% ($5,799.8M) with EPS of $3.12.1
Terminal growth rate reflects long-term economic expansion with the terminal valuation multiple maintaining a sustainable premium to mature medtech peers.
The modal base case incorporates solid commercial execution, gradual adoption across core diabetes segments, and successful integration with automated insulin delivery partners Tandem and Beta Bionics. Operating leverage advances steadily as manufacturing line efficiencies offset competitive pricing pressures, yielding a present intrinsic fair value of $58.97.5
CMS grants broad type 2 basal reimbursement coverage in mid-2027 following CONNECT trial validation.5
Gross margin expands to ~66% and non-GAAP exceeds 26% driven by automated manufacturing at the Ireland plant and 15-day sensor platform migration.
§7 Entscheidungsbaum für ErgebnisseEN
Übertroffen
Upgrade the rating; Verify whether margin expansion stems from permanent scrap reduction or temporary rebate timing, and review distributor inventory days before adjusting exposure.
A beat exceeding the upper bounds of FY2026 guidance ($5.25B revenue and 24.0% non-GAAP operating margin) would demonstrate faster-than-modeled Ireland line absorption, narrowing the valuation gap sufficiently to warrant moving from Sell to Reduce.
Im Plan
Maintain Sell; Maintain disciplined liquidation schedule and reallocate proceeds to more attractively valued medical technology peers.
Auslöser: Full-year FY2026 revenue between $5.18B and $5.25B and non-GAAP operating margin between 23.5% and 24.0%.5
Results within guidance confirm ongoing operational progress but leave the stock overvalued at 28.25x forward earnings, keeping the share price well above the house fair value of $58.97 and maintaining the Sell stance.
Verfehlt
Maintain Sell; Accelerate full position exit and re-evaluate the platform moat durability if gross margin contracts.
A shortfall below guidance implies that pricing competition or international tender delays are impairing fundamentals, accelerating multiple derating toward mature peer levels and reinforcing our Sell rating.
Consensus estimate momentum has stabilized following the Q2 earnings release. Revisions for FY2026 EPS settled at $2.66 and FY2027 EPS at $3.12, while full-year FY2026 revenue consensus adjusted to $5,230.1M, mirroring management's raised guidance range of $5.18B-$5.25B.1,5
Wichtige Kennzahlen vor dem Bericht
01
Kennzahl:
CMS Basal Diabetes Reimbursement Determination
AktuellDecision expected from CMS before end of 2026, targeting mid-2027 implementation.
Warum es wichtig ist
Securing Medicare coverage for basal-only non-intensive diabetes unlocks an addressable pool of millions of US patients, representing the primary catalyst for top-line expansion in FY2027 and FY2028.
Cash flow generation is structurally robust: FY2025 operating cash flow reached $1,440.7M, delivering $1,077.2M of free cash flow on revenue of $4,662.0M. Working capital efficiency benefits from established wholesale pharmaceutical distributor partnerships (Customer A 55%, Customer B 35%, Customer C 46%), which insulate operating cash conversion from fragmented pharmacy collection terms. High cash conversion supports self-financed expansion of the Ireland plant.5,6,7,8
DexCom extracts substantial economic rents due to proprietary sensor technology and manufacturing automation. While initial startup absorption in Ireland and 15-day sensor conversion temporarily constrain capital turnover, line throughput improvements, scrap reductions, and expanding non-GAAP operating margins to 23.5%-24.0% sustain durable returns above capital costs.
ROIC of 16.43% comfortably exceeds WACC of 9.99% and moderate cost of equity of 10.23%, generating an excess return spread of 644 bps.
Operating leverage expansion is outpacing historical baseline performance.
FY2025 GAAP operating income was $911.8M (19.56% margin) on $4,662.0M revenue, while management raised full-year FY2026 non-GAAP to 23.5%-24.0%.
Jüngster Umsatz4,7 Mrd. $Umsatz-CAGR +26,2 %
Betriebsmarge19,6 %10 Geschäftsjahresperioden
Jüngster freier Cashflow1,1 Mrd. $FY2025
Nettoliquidität609 Mio. $FY2025
Aufschlüsselung der Gewinn- und VerlustrechnungWie sich die Unternehmensgröße in ausgewiesenen Gewinn übersetzt.30. Juni 2026
DexCom Inc. (DXCM) trades at 28.3x forward earnings against a peer median of 14.9x. Its EV/EBITDA of 22.6x compares with a peer median of 14.5x. The comparison uses 4 peers: Edwards Lifesciences Corporation, Boston Scientific Corporation, Stryker Corporation and Biogen Inc., as of 2026-10-04.
§10 Branche & ZyklusEN
Zyklusphase
Expansion
The medical equipment sector benchmark operates with an average capex-to-revenue ratio of 4.5% and capex-to-depreciation ratio of 0.80x. In contrast, DexCom is investing above industry norms: FY2025 capex was $363.5M on $4,662.0M in revenue (7.8% capex/revenue) and capex-to-depreciation stood at 1.44x ($363.5M / $251.8M) as the company constructs its automated manufacturing plant in Ireland.5,7
Bullenzyklus
Rapid continuous glucose monitoring adoption across 9 million US diabetes patients, positive CMS coverage for type 2 non-intensive diabetes taking effect in mid-2027, and international tender wins drive sustained double-digit revenue expansion that fully utilizes automated manufacturing scale.
Bärenzyklus
Payer consolidation, intensified pricing pressure from Abbott FreeStyle Libre, or delays in Medicare coverage expansion for type 2 diabetes lead to gross margin erosion below the guided 64% level, leaving newly added manufacturing capacity underabsorbed.
Säkulare Trends
Trend
Auswirkung
Hinweis
Secular Shift from Intermittent Blood Glucose Testing to Continuous Monitoring
positive
Clinical guidelines and patient preference increasingly favor real-time CGM over conventional fingersticks for intensive and non-intensive diabetes, supported by CONNECT trial outcomes showing significant A1C reductions.
Pervasive Integration of Automated Insulin Delivery Algorithms
positive
Diabetes management is moving toward closed-loop automated insulin delivery (AID), where DexCom sensors integrate with pump systems like Tandem and Beta Bionics to adjust insulin delivery automatically.
Positionierung
DexCom occupies a premium position in specialized diabetes medtech, generating an FY2025 GAAP EBIT margin of 19.56% ($911.8M) that outperforms the industry average operating margin of 15.5%. Furthermore, management has guided FY2026 non-GAAP operating margin to 23.5%-24.0%. However, with the stock trading at a forward P/E of 28.25x versus medtech peers SYK (16.47x) and BSX (12.49x), the market has aggressively priced in successful capital cycle execution.3,4,5,7
§11 PositionsmanagementEN
Positionsgröße
0%
Under our Sell rating, recommended equity weighting is 0%. DexCom trades at $85.36, representing a 44.75% premium over our synthesized fair value of $58.97. The unfavorable risk-reward asymmetry and negative implied return of -30.92% warrant a complete absence from the portfolio until market pricing aligns with intrinsic fundamentals.4
Risiko
Risk management is anchored in capital preservation given the stock's 44.75% premium over intrinsic fair value ($85.36 price vs $58.97 fair value). Investors holding existing long positions should execute an orderly, staged liquidation into prevailing market liquidity. Any residual exposure should be strictly hedged with a trailing stop or protective put options.
DexCom trades at a 44.8% premium to its Fair value of $58.97 and a forward P/E of 28.25x, well above established medtech peers such as BSX (12.49x) and SYK (16.47x). With zero margin of safety and supporting models yielding cash flow values as low as $38.97, value-oriented investors should avoid the stock.3,4
Growth Investor
Hold
Growth investors may note solid top-line momentum with FY2026 guided revenue growth of 11%-13% ($5.18B-$5.25B) and expansion into Type 2 diabetes via CONNECT trial data. However, with the October 2, 2026 share price of $85.36 surpassing even our optimistic bull-case valuation of $74.00, new capital allocation cannot be justified.4,5
Income / Defensive Investor
Avoid
DexCom pays no dividend and allocates capital toward factory expansion and automated line investments ($363.5M capex in FY2025). Combined with an adjusted beta of 1.2043 and high revenue concentration through three wholesale distributors, the shares offer no yield and carry substantial multiple compression risk.2,5,7,8
§14 Endgültige EmpfehlungEN
Aktion
Verkaufen
At the October 2, 2026 share price of $85.36, DexCom shares trade at a 44.8% premium to our compositeFair value of $58.97, implying -30.9% downside. While DexCom maintains a strong continuous glucose monitoring platform moat and expanding Type 2 diabetes opportunities, its forward P/E of 28.25x trades at an excessive premium to diversified medtech peers (EW at 25.21x, SYK at 16.47x, BSX at 12.49x).3,4,5
Valuation models anchoring on forward earnings ($66.90 midpoint) and multi-stage moat fade ($62.17 midpoint), alongside enterprise DCF ($38.97 midpoint) and owner earnings ($53.02 midpoint), indicate that current market pricing leaves zero margin of safety against potential CMS coverage delays past mid-2027 or gross margin compression from pharmacy rebate pressure. We recommend liquidating or trimming positions to reallocate capital into assets offering an appropriate margin of safety.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
CMS defers type 2 basal reimbursement coverage past 2027 and international tender growth slows, dragging 5-year revenue CAGR down by 5 percentage points.
Current consensus models FY2026 revenue of $5,230.1M (12.19% growth) and FY2027 revenue of $5,799.8M (10.89% growth), heavily reliant on CMS basal T2 coverage taking effect in mid-2027 and international revenue expansion beyond $1,327.1M.1,5,8
FV impact
-4%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 24 months
CGM market matures and growth slows toward broad medtech peer rates, causing terminal P/E multiple to contract by 20% toward mature peer medians.
DexCom currently trades at a forward P/E of 28.25x, well above diversified medtech peers SYK (16.47x) and BSX (12.49x). If terminal multiple derates by 20% from 24.0x to 19.2x, compositefair value contracts significantly.3,4
Lumpiness in international government procurement tenders and national reimbursement timing causes non-US revenue growth to decelerate below 8.0%, undermining geographic expansion assumptions.
Operating leverage unwinds toward the FY2025 GAAP EBIT margin baseline of 19.56% ($911.8M on $4,662.0M revenue) due to unabsorbed startup costs at the Ireland manufacturing plant.
Aktuell:23.75% (midpoint of FY2026 guidance 23.5%-24.0%)
Alarm, wenn< 20.5%
04
Wholesale Distributor Channel Throughput
Inventory de-stocking or contractual dispute by a key national pharmaceutical wholesaler disrupts quarterly product fulfillment, causing sudden revenue drag and working capital expansion.
Aktuell:Customer A 55%, Customer B 35%, Customer C 46% share of FY2025 revenue
03Wholesale Distribution Intermediary Network Scale — Established wholesale distribution agreements with national distributors—Customer A representing 55%, Customer B 35%, and Customer C 46% of revenue in reported periods —secure pervasive shelf space across retail pharmacies and medical clinics nationwide.Moderate
Customer concentration among major pharmaceutical wholesalers causing quarterly shipment lumpiness and inventory de-stocking volatility.
medium
6-12 months
End-market demand is driven by patient prescriptions across 9 million US individuals with diabetes, and operating cash flow remains strong ($1,440.7M in FY2025), confirming low structural credit risk.5,7
Potential delay in CMS reimbursement coverage expansion for basal and non-insulin type 2 diabetes past mid-2027.
medium
12-18 months
Clinical evidence from the CONNECT trial demonstrates statistically significant A1C reductions and high patient adherence, which management has submitted to CMS to anchor favorable coverage.5
43,1%
Method
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Discounted forecast-period cash flows (9,24 $) plus discounted terminal value (28,12 $) minus signed per current share (-1,61 $) equals the 38,97 $ lens value shown above. Negative net debt is , so subtracting it raises value.
Under the bull scenario, favorable reimbursement expansion into non-intensive diabetes broadens the accessible patient population significantly, while automated manufacturing yields at the newly commissioned Ireland facility accelerate operating leverage. Sensor migration to extended-wear formats lowers unit production costs, expanding free cash flow generation annually.
Serves as proof that automated manufacturing throughput gains and scrap reductions are overcoming raw material inflation and competitive pricing friction.
03
Kennzahl:
Commercial Ramp of Automated Ireland Facility
AktuellCommercial production scheduled to begin later in 2026.
Warum es wichtig ist
Expands manufacturing capacity to serve European and international markets locally, reducing cross-border freight costs and improving gross marginleverage.
04
Kennzahl:
Installed Base Migration to Extended-Wear Sensor Platforms
AktuellOngoing multi-year platform rollout transitioning users to 15-day sensors and G8.
Warum es wichtig ist
Longer sensor duration reduces annual sensor unit requirements per patient, structurally lowering cost of sales and supporting gross margin expansion toward management guidance targets.
05
Kennzahl:
Wholesale Distributor Order Patterns and DSO
AktuellCustomer A 55%, Customer B 35%, Customer C 46% of reported revenue.
Warum es wichtig ist
Ensures that recorded revenue reflects true patient prescription uptake across 9 million US individuals rather than temporary distributor inventory build.5
DexCom maintains a disciplined capital allocation strategy focused on high-return organic manufacturing investments, R&D for next-generation platforms (15-day sensors and G8), and strategic software capabilities such as Nutrisense. In FY2025, capex was $363.5M alongside stock-based compensation of $159.6M. Balance sheet liquidity is healthy, with $917.7M in cash against $1,389.7M in total debt as of year-end FY2025. The company pays no dividend, utilizing free cash flow to self-fund international manufacturing capacity and offset share dilution.
